Shattuck Labs Investor Relations Material

Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create biologic therapies that enhance the body's immune response. Shattuck Labs' technology is designed to modulate immune pathways, potentially improving outcomes for patients with challenging conditions. The company is involved in research and development efforts, advancing its immunotherapy candidates through clinical trials. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.